John Migas, MD
Medical Oncology · Normal, ILNPI 1629076971
Payments from drug & device makers
Across 264 payments — averaging $810.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Incyte Corporation$76K
- Pfizer$74K
- Astrazeneca UK Limited$32K
- Pharmacyclics LLC, An Abbvie Company$15K
- Jazz Pharmaceuticals Inc.$12K
- Novartis$4K
- plus $753 from 18 others
Across 10 payments — averaging $1209.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$12K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Incyte Corporation | 89 | $76,448 |
| Pfizer | 23 | $73,857 |
| Astrazeneca UK Limited | 6 | $32,163 |
| Pharmacyclics LLC, An Abbvie Company | 100 | $15,100 |
| Jazz Pharmaceuticals Inc. | 5 | $11,981 |
| Novartis | 6 | $3,541 |
| Johnson & Johnson | 4 | $149 |
| Astellas Pharma US Inc | 5 | $95 |
| Genentech USA, Inc. | 5 | $84 |
| AbbVie | 2 | $51 |
| Eisai Inc. | 2 | $46 |
| Bristol Myers Squibb | 2 | $46 |
| Sanofi | 2 | $42 |
| Taiho Oncology, Inc. | 2 | $35 |
| E.r. Squibb & Sons, L.L.C. | 2 | $33 |
| Amgen | 1 | $29 |
| Seagen Inc. | 1 | $23 |
| Boehringer Ingelheim | 1 | $21 |
| Sobi, Inc | 1 | $20 |
| ADC Therapeutics America, Inc. | 1 | $20 |
| AstraZeneca | 1 | $18 |
| GSK | 1 | $17 |
| Array Biopharma Inc | 1 | $12 |
| Gilead | 1 | $12 |
How this compares
$213,842 in reported general payments places this provider in the 70th percentile of 144 medical oncology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other medical oncology in Normal
- Andrzej JakubowiakChicago$42M
- Alexander PearsonChicago$9.3M
- Jyoti PatelChicago$7.5M
- Devalingam MahalingamChicago$7.1M
- Ardaman ShergillChicago$4.9M
- Sunandana ChandraChicago$4.6M
- William GradisharChicago$3.3M
- Manali BhaveChicago$3.3M
- Eugene AhnChicago$2.8M
- James WadeDecatur$2.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.